Xcout Intel
Amplifica, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Amplifica, Inc. among biotechnology companies — ranked by similarity to what Amplifica, Inc. actually does, not by market-cap band.
Subscribe to see Amplifica, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Amplifica, Inc.
Amplifica Holdings Group, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing novel treatments for androgenic alopecia.
Amplifica, Inc. at a glance
Amplifica, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series A, raised $26M in August 2026. Xcout tracks 5 named people at Amplifica, Inc., including Frank Fazio (President and Chief Executive Officer).
Amplifica, Inc. leadership
- Frank FazioPresident and Chief Executive Officer
- Hans HoflandChief Development Officer
- WAJDIE AHMADCo-Founder, Executive Chairman and COO
- FAUAD HASANCo-Founder
- William HumphriesBoard Member
Amplifica, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $26M | 1 named | |
| — | $11.8M | 3 named | |
| SEC Form D filing | $500,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Amplifica, Inc. competitors
Ranked by semantic similarity — how close each company is to Amplifica, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Amplica Bio, Inc. is a biotechnology company that develops next-generation biologics and therapies aimed at targeting difficult diseases. The company engages in drug engineering to address challenging therapeutic targets.
Similar biotechnology company
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Similar biotechnology company
cAMPfield Therapeutics is a biotechnology research company headquartered in San Diego, California. The company focuses on discovering and developing innovative therapeutic treatments targeting specific biological pathways.
Similar biotechnology company
Autobahn Therapeutics, Inc. is a privately held biopharmaceutical company with its corporate office and headquarters located in San Diego, California, focused on restoring hope for patients.
Biotech
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Similar biotechnology company
Autobahn Therapeutics is a biotechnology company headquartered in San Diego, California, focused on developing restorative treatments in the medical sector.
Similar biotechnology company
Aldena Therapeutics is a biotechnology company focused on transforming dermatology through novel siRNA-based treatments for skin conditions.
Biotech
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Similar biotechnology company
Ambros Therapeutics is a clinical-stage biotechnology company headquartered in Irvine, California, focused on the development of innovative therapeutics.
Similar biotechnology company
Inmagene Biopharmaceuticals is a clinical-stage biotechnology company headquartered in San Diego, California. The firm is dedicated to the research, development, and advancement of novel therapeutic medicines. It operates within the life sciences sector, focusing on clinical development and corporate mergers.
Biotech
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
Similar biotechnology company
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Amplifica, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Amplifica, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →